Oslo, Norway (30 June 2020)

At the Annual General Meeting (“AGM”) today of Kaydence Pharma AS (“Kaydence Pharma”) it has been decided that NattoPharma ASA (“NattoPharma”) will convert NOK 4 million of its loans to equity in Kaydence Pharma. The loan will be converted at NOK 5 per share giving NattoPharma a total number of 3 000 000 shares representing a 54.15% interest as at 30 June 2020. Following the conversion, NattoPharma´s loan to Kaydence Pharma is NOK 51 million.

Further the AGM decided that the Board of Kaydence Pharma has been replaced with Kjetil Ramsøy as Chairman of the Board and Robert Schrama as Director.

“The increase in ownership further secures NattoPharma’s claim patents and is therefore in line with our strategy”, says Mr. Ramsøy. Erik Flatmark, the former Chairman of Kaydence Pharma, says: “I am happy that NattoPharma has taken this step in further securing control of Kaydence after the activities had been suspended earlier this year.”

Following these two decisions by the AGM, NattoPharma will have a controlling interest and Kaydence Pharma will be part of the consolidated accounts of NattoPharma going forward. The impact of the conversion will be reflected in the Q2 financials.


For more information, please contact:

Robert Schrama, CFO

E-mail: robert.schrama@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.


Documents & Links